Clinical Topics

December 2014 Focus

by U.S. Medicine

January 5, 2015

In this Issue:

Focus on HIV-HCV
New Treatments Offer More Options, Fewer Side Effects for HIV-Infected Veterans Despite High Costs, VA Makes Sure Veterans Have Access to Newest HCV Drugs
Pharmacy Update
Partnerships, Drive-Throughs Seek to Increase Veterans’ Flu Immunization
Gout Clinical Consult
Allopurinol Reduces Death Rate in Gout Patients
Dermatology Clinical Consult
Consensus Report Touts Lasers for Scar Treatment


Skin Cancer Risk High During Deployment NASHVILLE – Military personnel deployed abroad in climates such as Afghanistan and Iraq have increased risk factors for skin cancer, according to a new study. The increased risk is especially serious when servicemembers serve in tropical and sunny climates, according to a presentation at the World Congress on Cancers of the Skin. Researchers from the Tennessee Valley VA Healthcare System and Vanderbilt University conducted a retrospective study of about 200 veterans and found that 62% of military personnel reported getting sunburned while deployed abroad, including cases of skin blistering. More http://www.usmedicine.com/agencies/department-of-defense-dod/skin-cancer-risk-high-during-deployment/
David Rimland
New Treatments Offer More Options, Fewer Side Effects for HIV-Infected Veterans ATLANTA – Therapeutic options for patients with human immunodeficiency virus (HIV) continue to expand, enabling more veterans to begin treatment with fewer adverse side effects and far less complicated regimens than even a few years ago. Furthermore, with HIV, unlike many other conditions, dissemination of information on new treatments is extremely rapid. That’s good news for the more than 24,000 HIV-infected veterans who receive healthcare through the VA. Recent studies may bring even better tidings to veterans who have been unable to take or tolerate the most common combinations of HIV medications. More http://www.usmedicine.com/agencies/department-of-veterans-affairs/new-treatments-offer-more-options-fewer-side-effects-for-hiv-infected-veterans/ Despite High Costs, VA Makes Sure Veterans Have Access to Newest HCV Drugs WASHINGTON – While commercial insurers responded to the approval of the breakthrough drug sofosbuvir for hepatitis C (HCV) by implementing prescribing restrictions, limiting use to the sickest patients and charging higher co-pays because of the drug’s expense, the VA has left use of the drug up to the physician and patient to determine. VA guidelines issued in May recommend use of the drug for treatment of HCV genotypes 1, 2 or 3 with or without co-infection with human immunodeficiency virus (HIV). As of September, 5,500 veterans have taken sofosbuvir. More http://www.usmedicine.com/agencies/department-of-veterans-affairs/despite-high-costs-va-makes-sure-veterans-have-access-to-newest-hcv-drugs/
Partnerships, Drive-Throughs Seek to Increase Veterans’ Flu Immunization SAN FRANCISCO – The VA typically has influenza vaccination rates well above the national average but is trying some innovative measures to do even better. As part of the effort to increase immunizations, particularly among higher-risk veterans, the agency recently announced a national partnership with Walgreens to enable veterans to receive a flu shot at any of the chain’s retail pharmacies. Overall, more than 70% of veterans receive influenza immunizations each year, but the VA wants to increase the rate to more than 90% among high-risk individuals. More http://www.usmedicine.com/agencies/department-of-defense-dod/partnerships-drive-throughs-seek-to-increase-veterans-flu-immunization/
Allopurinol Reduces Death Rate in Gout Patients BOSTON – Despite fears of a rare but potentially fatal adverse reaction with use of allopurinol, the drug modestly reduces risk of death in patients with hyperuricemia and gout, according to a recent study. The article, published recently in The Annals of the Rheumatic Diseases, noted that gout itself has been associated with an increased risk of premature death and that the rare reaction to allopurinol, which can lead to death, affects only about 1 in 260 allopurinol users. Despite reluctance among some physicians to prescribe the drug because of the possiblity of severe skin reactions, it remains one of the most widely prescribed for gout. More http://www.usmedicine.com/current-issue/allopurinol-reduces-death-rate-in-gout-patients/
Consensus Report Touts Lasers for Scar Treatment BOSTON – Patients with disfiguring and debilitating scars suffer poor cosmetic outcomes, restricted motion, pain and itching, despite traditional therapy such as expert wound care. A consensus report published earlier this year in JAMA Dermatology discusses a breakthrough within the past decade in the treatment of traumatic scars and the restoration of function and cosmetic appearance for injured patients, ablative fractional photothermolysis. The study group, led by researchers from Massachusetts General Hospital Boston and including representatives from Lackland Air Force Base, TX, and the Naval Medical Center in San Diego, lamented, however, that the procedure is not widely used. More http://www.usmedicine.com/agencies/department-of-defense-dod/consensus-report-touts-lasers-for-scar-treatment/
Brenda L. Mooney Editorial Director, U.S. Medicine [email protected] 39 York Street Lambertville, NJ  08530 Advertise in this Newsletter | E-mail Privacy Policy

Comments are closed here.

Related Articles

HIV Patients Had Lower PC Incidence in VA Study

NEW YORK—Non-AIDS defining cancers are increasingly important contributors to health outcomes for aging persons with HIV (PWH), according to a recent conference presentation. The presentation also pointed out that, although prostate cancer is prevalent in... View Article

Oral Cancer Therapies Create Critical Demand for Pharmacists

CHICAGO—The pace of U.S. Food and Drug Administration approval of oral anticancer medications has rapidly increased, from less than one a year at the turn of the century to 10 in 2018. While patients generally... View Article

U.S. Medicine Recommends

More From oncology


Overcoming Radiation Resistant Prostate Cancer

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article


JAK Enzymes Can Treat Leukemia, Lymphoma

NASHVILLE, TN—Precision oncology prescribes the use of molecularly-targeted therapy directed by identification of genomic alterations. A new study suggested the approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, such as... View Article


Response of Veterans to PD-1 Checkpoint Inhibitors

RENO, NV—The clinical outcomes and the incidence of adverse events for programmed death-1 checkpoint inhibitors in cancer patients at a VA clinic were different from the data that have been published, according to a new... View Article


Surgical Staging Often Inadequate for Gallbladder Cancer

Guidelines frequently aren’t followed when it comes to radical cholecystectomy with regional lymphadenectomy for patients with T1b gallbladder cancer.


Use of Hospice During Treatment Has Limited VA Use

Unlike in most private sector settings, veterans with advanced cancer can receive hospice care concurrently with treatments such as radiation and chemotherapy.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up